News

Sarepta Stock Sinks. How Its Crisis Went From Bad to Worse.
Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, ...
Sarepta Therapeutics: Why Is SRPT Stock Crashing?
The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.
Sarepta: Finally, A Little Relief For Bulls; I Expect More
Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...
Sarepta Therapeutics Provides Statement on ELEVIDYS
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: ...
Sarepta Therapeutics: What's Happening With SRPT Stock?
The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...
Sarepta Therapeutics crisis is huge blow to Duchenne families, company
Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...
Business Wire4d
Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced a strategic restructuring plan ...
Seeking Alpha1y
Sarepta Therapeutics: Pushing The Edge And Creating The Horizon
Sarepta Therapeutics (NASDAQ:SRPT) has always been pushing the edge of biotech by advancing therapies for several rare diseases using RNA therapies, gene therapies, and gene editing.Not only has ...